OpGen, which provides genetic tests that identify patients with multi-drug resistant bacterial infections, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering.
The genetic testing space has recently seen heightened IPO activity. RainDance Technologies (RAIN) filed on Friday and HTG Molecular (HTGM) recently updated its financials. Invitae (NVTA) went public in February while two other genetic testing companies (AGMX, IDGX) postponed IPOs.
The company names Fluidigm (FLDM) as a supplier and Cepheid (CPHD) and Nanosphere (NSPH) as competitors.
The Gaithersburg, MD-based company, which was founded in 2001 and booked $4 million in sales for the 12 months ended December 31, 2014, plans to list on the NASDAQ under the symbol OPGN. OpGen initially filed confidentially on November 24, 2014. Maxim Group is the sole bookrunner on the deal. No pricing terms were disclosed.
